DNA Capitals
Overview
DNA Capitals is a data science advisory and training company based in Singapore. The firm is committed to driving business impact for organizations through consultancy and learning programs focused on data strategy, predictive analytics, operational efficiency, and risk mitigation. It aims to advance the data capabilities of organizations and their employees by delivering customized data science knowledge and technical skills. The company was founded in 2017 by Catherine Khaw.
Portfolio Companies
7
Website
dnacapitals.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Clover Health | May 2017 | Series D | - |
| Beep Saúde | Nov 2022 | Series C | - |
| Sanar | Apr 2020 | Series B | - |
| The CareVoice | Sep 2021 | Series B Extension | - |
| Memed | Jun 2021 | Buyout/LBO | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is DNA Capitals based?
DNA Capitals is headquartered in Singapore, Central Singapore, Singapore.
When was DNA Capitals founded?
Founding year information for DNA Capitals is not publicly available.
How many portfolio companies does DNA Capitals have?
DNA Capitals has 7 portfolio companies in Caplight's dataset.
What are some companies in DNA Capitals's portfolio?
Portfolio companies visible on Caplight include Clover Health, Beep Saúde, Sanar, The CareVoice, Memed.
What was DNA Capitals's most recent investment shown here?
DNA Capitals's most recent investment in this portfolio sample was in Beep Saúde in 2022.
What sectors does DNA Capitals focus on?
DNA Capitals focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, FinTech, Healthcare & Life Sciences, Healthcare & Life Sciences, Enterprise Software, Enterprise Software, Enterprise Software, Enterprise Software, Consumer & Commerce.
What company stages does DNA Capitals focus on?
DNA Capitals typically invests at the Late stage.